A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

In SURMOUNT-1, patients taking a weekly injection of the drug saw ... between differently-designed studies. Tirzepatide is hugely important for Lilly, as its once-weekly GLP-1 agonist for diabetes ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

What happened: In early October, the FDA determined that Eli Lilly’s tirzepatide injection shortage had been resolved. The U.S. health regulator reminded compounders of the legal restrictions on ...

Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Phase 3 trials are expected to last until January 2026, so the injection won’t be up for FDA approval for a few years. A Lilly rep declined to comment to The Post. Tirzepatide, a weekly GLP-1 ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...